Mineralys (MLYS) CFO receives 53,300 options and 39,900 RSUs in equity awards

Rhea-AI Filing Summary

Levy Adam Scott reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics CFO Adam Scott Levy reported equity awards consisting of stock options and restricted stock units. He was granted 53,300 stock options and RSUs covering 39,900 shares of common stock, each at a reported price of $0.00 per share as compensation rather than open-market purchases.

The RSUs were granted for no additional cash consideration and represent contingent rights to receive common stock upon vesting. They vest in four equal annual installments on each one-year anniversary of the grant date. The stock options vest separately in 48 equal monthly installments over four years, with 1/48th of the option vesting each month after the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Levy Adam Scott

Role CFO and Secretary

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	53,300	$0.00	--
Grant/Award	Common Stock	39,900	$0.00	--

Holdings After Transaction: Stock Option — 53,300 shares (Direct); Common Stock — 48,538 shares (Direct)

Footnotes (1)

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Adam Scott

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		A		39,900(1)	A	$0	48,538	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$28.06	02/19/2026		A		53,300		(2)	02/19/2036	Common Stock	53,300	$0	53,300	D

Explanation of Responses:

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.

2. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant

Remarks:

	/s/ Adam Levy	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mineralys Therapeutics (MLYS) CFO Adam Scott Levy report on this Form 4?

Adam Scott Levy reported equity awards in the form of stock options and restricted stock units. He was granted 53,300 stock options and RSUs for 39,900 shares of common stock as part of compensation, not open-market trading activity.

How many stock options did the Mineralys Therapeutics (MLYS) CFO receive?

The CFO received 53,300 stock options. These options vest over four years in 48 equal monthly installments, with 1/48th of the total options becoming exercisable each month following the grant date, reflecting a long-term incentive structure.

What restricted stock unit (RSU) grant did the Mineralys Therapeutics (MLYS) CFO disclose?

He disclosed a grant of restricted stock units covering 39,900 shares of common stock. The RSUs were granted for no additional cash consideration and each RSU converts into one share of common stock upon vesting, subject to the specified vesting schedule.

How do the Mineralys Therapeutics (MLYS) CFO’s RSUs vest over time?

The RSUs vest in four annual installments. Specifically, one-quarter of the 39,900 underlying shares vests on each one-year anniversary of the grant date, creating a four-year vesting period tied to continued service with the company.

What is the vesting schedule for the Mineralys Therapeutics (MLYS) CFO’s stock options?

The stock options vest in 48 monthly installments over four years. Each month after the grant date, 1/48th of the 53,300 options vests, gradually increasing the portion of options that become exercisable as time passes.

Were the Mineralys Therapeutics (MLYS) equity awards to the CFO open-market purchases?

No, these were compensatory grants rather than market purchases. The Form 4 shows a transaction code of "A" for awards and a price of $0.00 per share, indicating they were granted to the CFO without additional cash consideration.